Abstract: A compound of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Abstract: Compounds of formula I, wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: A compound of formula wherein R1 is haloalkyl, alkenyl, phenyl, thienyl, pyridine, benzthiazolyl, chromanyl (1,2-dihydrobenzopyranyl) or (C6-18)aryl, and R1 or R2 independently of each other are substituted (C4-8)cycloalkyl, a substituted bridged cycloalkyl system, substituted piperidine, substituted tetrahydropyridine, or a substituted bridged heterocyclic system, useful as a pharmaceutical.

Abstract: The present invention relates to a method (assay) for determining the activity of an enzyme selected from the group consisting of a sphingosine kinase and a phosphatase involved in the sphingolipid pathway by use of a labeled sphingosine.

Abstract: The use of a metathesis catalyst in the preparation of a functionalized sphingolipid.

Abstract: treatment of a variety of disorders, including the treatment of pathological conditions associated with tumor necrosis factor alpha. The inhibitors of tumor necrosis factor alpha have the following structures: including stereoisomers, pharmaceutically acceptable salts, and solvates thereof, wherein substituents are as defined herein. Compositions containing an inhibitor of tumor necrosis factor alpha in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

Abstract: A compound of formula (I) wherein R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses, in particular in transplantation, and pharmaceutical compositions containing them.

Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.

Abstract: The invention concerns momoclonal antibodies to terbinafine in free base or salt form, immunogenic conjugates suitable for preparing them, hybridoma capable of producing them, and corresponding assay kits. The antibodies can be prepared by administering to an appropriate animal an immunogenic conjugate of a suitable derivative of terbinafine covalently linked to an immonogen, recovering antibody-producing cells sensitized to the conjugate, immortalizing the antibody-producing cells, selecting a resultant immortalized cell line, and recovering the resultant antibodies therefrom. They are indicated for use in particular in the measurement of terbinafine tissue concentration and distribution in bodily fluids or compartments, especially nails.

Abstract: Compounds of formula I, wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: A compound of formula wherein R1 is haloalkyl, alkenyl, phenyl, thienyl, pyridine, benzthiazolyl, chromanyl (1,2-dihydrobenzopyranyl) or (C6-18)aryl, and R1 or R2 independently of each other are substituted (C4-8)cycloalkyl, a substituted bridged cycloalkyl system, substituted piperidine, substituted tetrahydropyridine, or a substituted bridged heterocyclic system, useful as a pharmaceutical.

Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them.

Abstract: The invention concerns monoclonal antibodies to terbinafine in free base or salt form, immunogenic conjugates suitable for preparing them, hybridoma capable of producing them, and corresponding assay kits. The antibodies can be prepared by administering to an appropriate animal an immunogenic conjugate of a suitable derivative of terbinafine covalently linked to an immunogen, recovering antibody-producing cells sensitized to the conjugate, immortalizing the antibody-producing cells, selecting a resultant immortalized cell line, and recovering the resultant antibodies therefrom. They are indicated for use in particular in the measurement of terbinafine tissue concentration and distribution in bodily fluids or compartments, especially nails.

Abstract: The invention concerns the compounds of formula I wherein R1 and R2 independently are hydrogen, acyl, alkoxycarbonyl or alkyl; either the sulfamoyloxy side chain is bound to the 6 position; R3 is alkyl; alkenyl; alkinyl; a cycloalkyl moiety optionally substituted by alkyl, alkoxy or halogen; arylalkenyl; arylalkinyl; acyl; cycloalkylalkyl; 3-oxo-2-oxacamphanyl; or is 6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl; and R4 is hydrogen; alkyl; hydroxy; or alkoxy; or the sulfamoyloxy side chain is bound to the 7 position; R3 has the significance indicated above for R4; and R4 has the significance indicated above for R3; X is O or S; and the symbol - - - is a single or a double bond; in free form or salt form. They can be prepared by sulfamoylation of corresponding hydroxylated compounds, by reduction and/or by N-substitution. They are indicated for use as pharmaceuticals, particularly in the prophylactic or curative treatment of illnesses responsive to steroid sulfatase inhibition.

Abstract: The invention concerns compounds of formula I ##STR1## wherein the substituents have various meanings, and their use in the prevention or treatment of inflammatory and proliferative skin diseases and cancer.

Abstract: The invention relates to a blocked polyisocyanate having an NCO functionality of from 2.2 to 4.5 and an average molecular weight of 800 to 25,000 and containing (1) blocked isocyanate groups corresponding to an NCO content of 5 to 20 wt. % calculated as free NCO, relative to unblocked polyisocyanate, (2) 1 to 75 meq of ionic groups per 100 g of blocked polyisocyanate, and (3) 3 to 40 wt.

Abstract: The invention relates to a blocked polyisocyanate having an NCO functionality of from 2.2 to 4.5 and an average molecular weight of 800 to 25,000 and containing (1) blocked isocyanate groups corresponding to an NCO content of 5 to 20 wt. % calculated as free NCO, relative to unblocked polyisocyanate, (2) 1 to 75 meq of ionic groups per 100 g of blocked polyisocyanate, and (3) 3 to 40 wt.

Abstract: The invention concerns the compounds of formula I ##STR1## wherein the substituents have various significances, in free form and, where such forms exist, in salt form. The compounds have potent antihyperproliferative/antiinflammatory and anticancer activity.

Abstract: Phobicity effects of high quality and permanence are obtained on textile materials of the most diverse types if these are finished with combinations ofA) a polymer containing perfluoroalkyl groups andB) a cationically modified polyurethane.The new compositions are also distinguished by a comparatively low content of expensive fluorine compounds.

Abstract: The present invention relates to water-dispersible polyetherester-modified polyurethane ionomers containing 10 to 100 milliequivalents of ionic, preferably cationic, groups per 100 g of ionomer; 2 to 40% by weight of polyetherester groups; and 1 to 35% by weight of ethylene oxide units, in which the percentages are based on the weight of the polyetherester-modified polyurethane ionomer.The present invention also relates to a process for the preparation of these polyetherester-modified polyurethane ionomers and to aqueous compositions containing these polyetherester-modified polyurethane ionomers and polymers containing perfluoralkyl groups.